Abstract
The pattern of insulin release is crucial for regulation of glucose and lipid haemostasis. Deficient insulin release causes hyperglycemia and diabetes, whereas excessive insulin release can give rise to serious metabolic disorders, such as nesidioblastosis (Persistent Hyperinsulinemic Hypoglycemia of Infancy, PHHI) and might also be closely associated with development of type 2 diabetes and obesity. Type 2 diabetes is characterized by fasting hyperinsulinemia, insulin resistance and impaired insulin release, i.e. reduced first phase insulin release and decreased insulin pulse mass. The beta cell function of patients with type 2 diabetes slowly declines and will ultimately result in beta cell failureand increasing degrees of hyperglycemia. Type 2 diabetes, in combination with obesity and cardiovascular disorders, forms the metabolic syndrome. It has been possible to improve beta cell function and viability in preclinical models of type 1 and type 2 diabetes by reducing insulin secretion to induce beta cell rest. Clinical studies have furthermore indicated that inhibitors of insulin release will be of benefit in treatment or prevention of diabetes and obesity. Pancreatic beta cells secrete insulin in response to increased metabolism and by stimulation of different receptors. The energy status of the beta cell controls insulin release via regulation of open probability of the ATP sensitive potassium (KATP) channels to affect membrane potential and the intracellular calcium concentration [Ca2+]i. Other membrane bound receptors and ion channels and intracellular targets that modulate [Ca2+]i will affect insulin release. Thus, insulin release is regulated by e.g. somatostatin receptors, GLP-1 receptors, muscarinic receptors, cholecystokinin receptors and adrenergic receptors. Although the relationship between hyperinsulinemia and certain metabolic diseases has been known for decades, only a few inhibitors of insulin release have been characterized in vitro and in vivo. These include the KATP channel openers diazoxide and NN414 and the somatostatin receptor agonist octreotide.
Keywords: beta cell, diabetes, diazoxide, insulin secretion, katp channel, n414, somatostatin
Current Medicinal Chemistry
Title: Inhibition of Insulin Secretion as a New Drug Target in the Treatment of Metabolic Disorders
Volume: 11 Issue: 12
Author(s): J. Bondo Hansen, Per O. G. Arkhammar, Thora B. Bodvarsdottir and Philip Wahl
Affiliation:
Keywords: beta cell, diabetes, diazoxide, insulin secretion, katp channel, n414, somatostatin
Abstract: The pattern of insulin release is crucial for regulation of glucose and lipid haemostasis. Deficient insulin release causes hyperglycemia and diabetes, whereas excessive insulin release can give rise to serious metabolic disorders, such as nesidioblastosis (Persistent Hyperinsulinemic Hypoglycemia of Infancy, PHHI) and might also be closely associated with development of type 2 diabetes and obesity. Type 2 diabetes is characterized by fasting hyperinsulinemia, insulin resistance and impaired insulin release, i.e. reduced first phase insulin release and decreased insulin pulse mass. The beta cell function of patients with type 2 diabetes slowly declines and will ultimately result in beta cell failureand increasing degrees of hyperglycemia. Type 2 diabetes, in combination with obesity and cardiovascular disorders, forms the metabolic syndrome. It has been possible to improve beta cell function and viability in preclinical models of type 1 and type 2 diabetes by reducing insulin secretion to induce beta cell rest. Clinical studies have furthermore indicated that inhibitors of insulin release will be of benefit in treatment or prevention of diabetes and obesity. Pancreatic beta cells secrete insulin in response to increased metabolism and by stimulation of different receptors. The energy status of the beta cell controls insulin release via regulation of open probability of the ATP sensitive potassium (KATP) channels to affect membrane potential and the intracellular calcium concentration [Ca2+]i. Other membrane bound receptors and ion channels and intracellular targets that modulate [Ca2+]i will affect insulin release. Thus, insulin release is regulated by e.g. somatostatin receptors, GLP-1 receptors, muscarinic receptors, cholecystokinin receptors and adrenergic receptors. Although the relationship between hyperinsulinemia and certain metabolic diseases has been known for decades, only a few inhibitors of insulin release have been characterized in vitro and in vivo. These include the KATP channel openers diazoxide and NN414 and the somatostatin receptor agonist octreotide.
Export Options
About this article
Cite this article as:
Hansen Bondo J., G. Arkhammar O. Per, Bodvarsdottir B. Thora and Wahl Philip, Inhibition of Insulin Secretion as a New Drug Target in the Treatment of Metabolic Disorders, Current Medicinal Chemistry 2004; 11 (12) . https://dx.doi.org/10.2174/0929867043365026
DOI https://dx.doi.org/10.2174/0929867043365026 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the Treatment of Chronic Inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Peri-Procedural Care of Renal Nerve Ablation Candidates
Current Clinical Pharmacology Enzyme Inhibitors
Current Bioactive Compounds Cardiac Remodeling and Exercise Training in Hypertension
Current Hypertension Reviews Cyclodextrin-Functionalized Hydrogels: A Novel Drug Delivery System for the Delivery of Hydrophobic Drugs
Current Drug Therapy Inflammation and Pancreatic Cancer: Recent Development with Focusing on Potential New Drug Targets
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Poly-Electrolyte Complex: A Novel System for Biomedical Applications and Recent Patents
Recent Patents on Nanotechnology Atherosclerosis and Inflammation: Insight from Carotid and Intracoronary Ultrasound Studies
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Statins in the Treatment of Acute Ischemic Stroke
Current Pharmaceutical Biotechnology Adiponectin, Structure, Function and Pathophysiological Implications in Non-Alcoholic Fatty Liver Disease
Mini-Reviews in Medicinal Chemistry Gender Differences in the Clinical Presentation of Heart Disease
Current Pharmaceutical Design Synthesis, Antioxidant and Anti-inflammatory Properties of an Apocynin- Derived Dihydrocoumarin
Medicinal Chemistry Double Edge Sword Behavior of Carbendazim: A Potent Fungicide With Anticancer Therapeutic Properties
Anti-Cancer Agents in Medicinal Chemistry Regulatory Requirements for PET Radiopharmaceuticals Production: Is Automation an Answer?
Current Medical Imaging Role of Osmolytes and their Transporter Systems in Pathogen Survival and Pathogenicity
Current Drug Metabolism The Vicious Circle of Leptin and Obesity
Current Nutrition & Food Science Finding the Smoking Gun: Protein Tyrosine Phosphatases as Tools and Targets of Unicellular Microorganisms and Viruses
Current Medicinal Chemistry The Role of Bax/Bcl-2 and Pro-Caspase Peptides in Hypoxia/Reperfusion-Dependent Regulation of MAPKERK: Discordant Proteomic Effect of MAPKp38
Protein & Peptide Letters Review of Bioinformatics and QSAR Studies of β-Secretase Inhibitors
Current Bioinformatics The Role of Statins in the Activation of Heme Oxygenase-1 in Cardiovascular Diseases
Current Drug Targets The Putative Impact of Metabolic Health on Default Mode Network Activity and Functional Connectivity in Neuropsychiatric Disorders
CNS & Neurological Disorders - Drug Targets